T. Rowe Price Associates
NVCR icon

T. Rowe Price Associates’s NovoCure NVCR Stock Holding History

T. Rowe Price Associates’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Buy
115,102
+21,008
+22% +$262K ﹤0.01% 2038
2025
Q4 		$1.22M Sell
94,094
-16,212
-15% -$208K ﹤0.01% 1994
2025
Q3 		$1.43M Buy
110,306
+4,555
+4% +$60.9K ﹤0.01% 1895
2025
Q2 		$1.88M Sell
105,751
-376,283
-78% -$6.56M ﹤0.01% 1666
2025
Q1 		$8.59M Sell
482,034
-1,201,784
-71% -$27.3M ﹤0.01% 1142
2024
Q4 		$50.2M Sell
1,683,818
-638,378
-27% -$13.5M 0.01% 753
2024
Q3 		$36.3M Buy
2,322,196
+166,175
+8% +$3.01M ﹤0.01% 842
2024
Q2 		$36.9M Sell
2,156,021
-222,919
-9% -$3.92M ﹤0.01% 811
2024
Q1 		$37.2M Buy
2,378,940
+125,715
+6% +$1.85M ﹤0.01% 800
2023
Q4 		$33.6M Sell
2,253,225
-111,234
-5% -$1.49M ﹤0.01% 811
2023
Q3 		$38.2M Sell
2,364,459
-181,006
-7% -$5.22M 0.01% 763
2023
Q2 		$106M Sell
2,545,465
-110,221
-4% -$6.84M 0.01% 511
2023
Q1 		$160M Buy
2,655,686
+487,255
+22% +$38.9M 0.02% 420
2022
Q4 		$159M Sell
2,168,431
-203,555
-9% -$15.3M 0.03% 416
2022
Q3 		$180M Buy
2,371,986
+40,619
+2% +$3.17M 0.03% 384
2022
Q2 		$162M Buy
2,331,367
+218,216
+10% +$16.4M 0.02% 533
2022
Q1 		$175M Buy
2,113,151
+626,983
+42% +$46.2M 0.02% 566
2021
Q4 		$112M Buy
1,486,168
+53,701
+4% +$5.39M 0.01% 728
2021
Q3 		$166M Sell
1,432,467
-137,018
-9% -$20.7M 0.02% 608
2021
Q2 		$348M Buy
1,569,485
+341,783
+28% +$66.5M 0.03% 424
2021
Q1 		$162M Sell
1,227,702
-10,502
-0.8% -$1.66M 0.02% 615
2020
Q4 		$214M Buy
1,238,204
+22,886
+2% +$3.13M 0.02% 509
2020
Q3 		$135M Buy
1,215,318
+34,051
+3% +$2.72M 0.02% 581
2020
Q2 		$70M Sell
1,181,267
-69,744
-6% -$4.59M 0.01% 740
2020
Q1 		$84.2M Sell
1,251,011
-79,626
-6% -$6.29M 0.01% 623
2019
Q4 		$112M Sell
1,330,637
-257,200
-16% -$20.8M 0.01% 633
2019
Q3 		$119M Sell
1,587,837
-769,645
-33% -$61.5M 0.02% 577
2019
Q2 		$149M Buy
2,357,482
+421,235
+22% +$21.3M 0.02% 532
2019
Q1 		$93.3M Buy
1,936,247
+9,668
+0.5% +$465K 0.01% 657
2018
Q4 		$64.5M Sell
1,926,579
-128,557
-6% -$4.7M 0.01% 731
2018
Q3 		$108M Buy
2,055,136
+1,373,617
+202% +$54.7M 0.02% 650
2018
Q2 		$21.3M Buy
+681,519
New +$19M ﹤0.01% 1180
2016
Q3 		– Sell
-2,580,593
Closed -$30.1M – 2550
2016
Q2 		$30.1M Sell
2,580,593
-7,872
-0.3% -$98.6K 0.01% 961
2016
Q1 		$37.5M Sell
2,588,465
-360
-0% -$5.17K 0.01% 883
2015
Q4 		$55.7M Buy
+2,588,825
New +$61.8M 0.01% 727

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

T. Rowe Price Associates's NVCR Position: Q1 2026 in Review

T. Rowe Price Associates increased its NovoCure (NVCR) stake by 22% in Q1 2026, buying an estimated $262K and bringing the position to 115,102 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

T. Rowe Price Associates first reported a position in NVCR in Q4 2015 and has held it in 35 quarters since. The position peaked at $348M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • T. Rowe Price Associates held 115,102 shares of NovoCure worth $1.25M as of Q1 2026.
  • T. Rowe Price Associates bought 21,008 NovoCure shares in Q1 2026, an estimated $262K.
  • NovoCure made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2038 holding.
  • T. Rowe Price Associates first reported a position in NovoCure in Q4 2015 and has held it in 35 quarters since.
  • T. Rowe Price Associates's NovoCure position peaked at $348M in Q2 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.